Zevra Therapeutics, Inc. (ZVRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zevra Therapeutics, Inc. on November 20, 2025. The filing discloses the resignation of the Company's Chief Financial Officer and Treasurer, R. LaDuane Clifton, effective December 31, 2025.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive personnel changes and associated compensation arrangements.
Material Changes
The primary material change is the departure of a key executive officer. Mr. Clifton is resigning to pursue other professional opportunities. The Company has initiated a search process to identify a replacement Chief Financial Officer.
Outlook, Risks, and Unusual Items
Separation Agreement Terms: In connection with the resignation, the Company entered into a Separation Agreement providing Mr. Clifton with the following benefits contingent upon compliance with restrictive covenants (non-disparagement, confidentiality, non-competition, and non-solicitation):
- 12 months of annual base salary, payable per normal payroll schedules.
- An annual bonus equal to 40% of his base salary.
- Up to 12 months of Company-paid COBRA continuation coverage.
- Full vesting of all outstanding equity awards.
Regulatory Disclosure: The Company issued a press release on November 20, 2025, regarding these matters, which is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Review the impact of the full vesting of equity awards on the Company's dilution and expense recognition.
- Confirm the total cash outflow associated with the 12-month salary and 40% bonus payment.
- Monitor subsequent filings for updates on the executive search process.